Shahrukh Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shahrukh Khan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Jafri
Department of Biotechnology, College of Science, Taif University, Taif, Saudi Arabia
2 shared publications - Nouf H. Alsubhi
Biological Sciences Department, College of Science & Arts, King Abdulaziz University, Rabigh 21911, Saudi Arabia
2 shared publications - Ramla Shahid
Department of Biosciences, COMSATS University Islamabad (CUI), Islamabad 45550, Pakistan
2 shared publications - Rokayya Sami
Department of Food Science and Nutrition, College of Sciences, Taif University
2 shared publications - Roua S. Baty
Department of Biotechnology, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia
2 shared publications - Ahmad Shaikh
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Kingdom of Saudi Arabia
1 shared publication
Latest Publications
- 4 June 2026
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 114 (6) , e70106
Multifunctional Nanoparticles for Theranostics of Protein Misfolding Diseases: A Systematic Review
Protein misfolding disorders such as Parkinson's disease, Alzheimer's disease, islet amyloidosis, and several other diseases (amyloidosis) are characterized by the pathological accumulation of misfolded proteins that aggregate into toxic oligomers and fibrils. These misfolded proteins trigger oxidative stress, disrupt cellular homeostasis, and ultimately lead to tissue dysfunction. Overcoming the limitations of conventional strategies, multifunctional nanoparticles have emerged as a promising solution for simultaneously detecting, monitoring, and modulating pathogenic protein aggregates, offering a synergistic approach to addressing the multifaceted challenges of protein misfolding diseases. This systematic review examined 85 relevant studies published between 2010 and 2025, identified through PubMed searches. Only experimental studies reporting multifunctional or dual‐functional nanoparticles for the theranostics of protein misfolding disorders were included. Data were narratively synthesized according to nanoparticle type, biomedical function, and therapeutic or diagnostic outcomes. The main findings suggest that multifunctional nanoparticles, including metallic, lipid, polymeric, carbon, silica, and hydrogel nanoparticles, can enable real‐time monitoring, enhance imaging resolution, improve delivery of anti‐amyloidogenic drugs, and mitigate oxidative stress and neuro‐inflammation. Some strategies demonstrate potential to cross the blood–brain barrier, selectively bind amyloid aggregates, and provide synergistic theranostic effects. Among these, magnetic nanoparticles are superior because they possess intrinsic diagnostic capabilities and can be used for therapy simultaneously, eliminating the need for additional diagnostic agents. Their multifunctional nature offers several advantages for precision nano‐theranostics in managing amyloidosis, though further translational studies are essential to establish scalability, safety, and long‐term clinical applicability.
- 4 June 2026
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 114 (6) , e70106
Multifunctional Nanoparticles for Theranostics of Protein Misfolding Diseases: A Systematic Review
Protein misfolding disorders such as Parkinson's disease, Alzheimer's disease, islet amyloidosis, and several other diseases (amyloidosis) are characterized by the pathological accumulation of misfolded proteins that aggregate into toxic oligomers and fibrils. These misfolded proteins trigger oxidative stress, disrupt cellular homeostasis, and ultimately lead to tissue dysfunction. Overcoming the limitations of conventional strategies, multifunctional nanoparticles have emerged as a promising solution for simultaneously detecting, monitoring, and modulating pathogenic protein aggregates, offering a synergistic approach to addressing the multifaceted challenges of protein misfolding diseases. This systematic review examined 85 relevant studies published between 2010 and 2025, identified through PubMed searches. Only experimental studies reporting multifunctional or dual‐functional nanoparticles for the theranostics of protein misfolding disorders were included. Data were narratively synthesized according to nanoparticle type, biomedical function, and therapeutic or diagnostic outcomes. The main findings suggest that multifunctional nanoparticles, including metallic, lipid, polymeric, carbon, silica, and hydrogel nanoparticles, can enable real‐time monitoring, enhance imaging resolution, improve delivery of anti‐amyloidogenic drugs, and mitigate oxidative stress and neuro‐inflammation. Some strategies demonstrate potential to cross the blood–brain barrier, selectively bind amyloid aggregates, and provide synergistic theranostic effects. Among these, magnetic nanoparticles are superior because they possess intrinsic diagnostic capabilities and can be used for therapy simultaneously, eliminating the need for additional diagnostic agents. Their multifunctional nature offers several advantages for precision nano‐theranostics in managing amyloidosis, though further translational studies are essential to establish scalability, safety, and long‐term clinical applicability.
- Open Access
- 20 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2985
Epithelial Cell Adhesion Molecule (EpCAM) Expression Can Be Modulated via NFκB
The epithelial cell adhesion molecule (EpCAM) is considered an essential proliferation signature in cancer. In the current research study, qPCR induced expression of EpCAM was noted in acute lymphoblastic leukemia (ALL) cases. Costunolide, a sesquiterpene lactone found in crepe ginger and lettuce, is a medicinal herb with anticancer properties. Expression of EpCAM and its downstream target genes (Myc and TERT) wasdownregulated upon treatment with costunolide in Jurkat cells. A significant change in the telomere length of Jurkat cells was not noted at 72 h of costunolide treatment. An in silico study revealed hydrophobic interactions between EpCAM extracellular domain and Myc bHLH with costunolide. Reduced expression of NFκB, a transcription factor of EpCAM, Myc, and TERT in costunolide-treated Jurkat cells, suggested that costunolide inhibits gene expression by targeting NFκB and its downstream targets. Overall, the study proposes that costunolide could be a promising therapeutic biomolecule for leukemia.
- 20 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2985
Open AccessEpithelial Cell Adhesion Molecule (EpCAM) Expression Can Be Modulated via NFκB
The epithelial cell adhesion molecule (EpCAM) is considered an essential proliferation signature in cancer. In the current research study, qPCR induced expression of EpCAM was noted in acute lymphoblastic leukemia (ALL) cases. Costunolide, a sesquiterpene lactone found in crepe ginger and lettuce, is a medicinal herb with anticancer properties. Expression of EpCAM and its downstream target genes (Myc and TERT) wasdownregulated upon treatment with costunolide in Jurkat cells. A significant change in the telomere length of Jurkat cells was not noted at 72 h of costunolide treatment. An in silico study revealed hydrophobic interactions between EpCAM extracellular domain and Myc bHLH with costunolide. Reduced expression of NFκB, a transcription factor of EpCAM, Myc, and TERT in costunolide-treated Jurkat cells, suggested that costunolide inhibits gene expression by targeting NFκB and its downstream targets. Overall, the study proposes that costunolide could be a promising therapeutic biomolecule for leukemia.
- Open Access
- 6 July 2022
- Published by MDPI AG in Applied Sciences
- Vol. 12 (14) , 6853
Estrogen Induces c-myc Transcription by Binding to Upstream ERE Element in Promoter
Estrogen Receptor α(ERα) is reported to regulate the expression of many target genes by binding to specific estrogen response elements (EREs) in their promoters. c-myc is known to be over-expressed in most of the human carcinomas due to dysregulated transcription, translation, or protein stability. Estrogen (E) can induce the c-myc expression by binding to an upstream enhancer element in its promoter. This suggests that elevated estradiol (E2), a potent form of estrogen, levels could induce the expression of c-myc in breast cancer (BC). The expression of c-myc and estradiol were induced at Stage III and Stage IV of breast cancer. c-myc and estradiol expression was also associated with the established risk factors of breast cancer, such as BMI. Age at the time of the disease was alsocorrelated with the relative expression of c-myc and estradiol (p < 0.0007 and p < 0.000001). The correlation coefficient (R = 0.462) shows a positive relationship between estradiol bound ER, ER, and c-myc. Docking energy −229 kJ/mol suggests the binding affinity of estradiol bound ER binding to 500 bp upstream of proximal promotor of c-myc at three distinct positions. The data presented in this study proposed that the expression of c-myc and estradiol are directly correlated in breast cancer. The prognostic utility of an induced level of c-myc associated with the normal status of the c-myc gene and estradiol for patients with metastatic carcinoma should be explored further.
- 6 July 2022
- Published by MDPI AG in Applied Sciences
- Vol. 12 (14) , 6853
Open AccessEstrogen Induces c-myc Transcription by Binding to Upstream ERE Element in Promoter
Estrogen Receptor α(ERα) is reported to regulate the expression of many target genes by binding to specific estrogen response elements (EREs) in their promoters. c-myc is known to be over-expressed in most of the human carcinomas due to dysregulated transcription, translation, or protein stability. Estrogen (E) can induce the c-myc expression by binding to an upstream enhancer element in its promoter. This suggests that elevated estradiol (E2), a potent form of estrogen, levels could induce the expression of c-myc in breast cancer (BC). The expression of c-myc and estradiol were induced at Stage III and Stage IV of breast cancer. c-myc and estradiol expression was also associated with the established risk factors of breast cancer, such as BMI. Age at the time of the disease was alsocorrelated with the relative expression of c-myc and estradiol (p < 0.0007 and p < 0.000001). The correlation coefficient (R = 0.462) shows a positive relationship between estradiol bound ER, ER, and c-myc. Docking energy −229 kJ/mol suggests the binding affinity of estradiol bound ER binding to 500 bp upstream of proximal promotor of c-myc at three distinct positions. The data presented in this study proposed that the expression of c-myc and estradiol are directly correlated in breast cancer. The prognostic utility of an induced level of c-myc associated with the normal status of the c-myc gene and estradiol for patients with metastatic carcinoma should be explored further.